Imaging test for solid tumors using MNPR-101-DFO*-89Zr
Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This study tests whether a new imaging agent, MNPR-101-DFO*-89Zr, can find solid tumors and measure their uPAR levels. It might help doctors better understand your cancer and guide future treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a solid tumor cancer.
- You are 18 years or older.
- You have had a recent PET/CT scan (within the last 2 months) showing at least one tumor larger than 1 cm.
- You have a tumor sample available for testing to see if it has a protein called uPAR.
- If you could become pregnant, you must have a negative pregnancy test and agree to use effective birth control during and for 1 month after the study.
- You must avoid breastfeeding for 1 month after receiving the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new radioactive drug called MNPR-101-PCTA-177Lu for people with solid tumors who already completed a previous study (MNPR-101-D001). It aims to find the safest and most effective dose by carefully monitoring how your body handles the treatment.
This trial tests a special imaging agent, [89Zr]DFO-YS5, to see if it can help detect and map certain cancers (including malignant peripheral nerve sheath tumors, bladder cancer, and other solid tumors) during PET scans. It may help doctors see cancerous lesions more clearly.
This study tests a special PET scan agent (an antibody tracer) to help doctors see EGFR-positive cancers without needing invasive procedures. It is mainly for early testing (Phase 1/2) to understand how well it works for imaging.
This Phase 1 study tests how safe RAD301 is and how it behaves in the body when given for PET imaging in healthy volunteers and people with certain cancers. It may help doctors learn whether this imaging drug can clearly show cancer areas and be tolerated well.
This study uses a special PET scan to see if a new imaging agent can help find and monitor certain solid tumors. It is for people with colon, rectal, sarcoma, breast, lung, head and neck, esophageal, stomach, pancreas, bladder cancers, or glioblastoma who have had standard treatment before surgery.
This trial tests a special imaging agent (a nanobody probe) that targets a protein called CD147 on tumor cells. If you have a solid tumor like melanoma, liver, colorectal, pancreatic, breast, stomach, or lung cancer, the PET scan may help doctors see your cancer more clearly.
Hear when a new Solid Tumor, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.